2022
Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
Savinkina A, Paltiel A, Ross J, Gonsalves G. Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis. Open Forum Infectious Diseases 2022, 9: ofac637. PMID: 36589482, PMCID: PMC9792084, DOI: 10.1093/ofid/ofac637.Peer-Reviewed Original ResearchCost-effectiveness analysisTrade-offs implicitSevere diseaseDecision analytic modelAllocation decisionsPay thresholdsPolicy strategiesUnvaccinated patientsVaccination statusHigh riskTreatment effectivenessHigh-risk individualsAllocation strategyPopulation-level strategiesWillingnessFurther priorityDrug costsSensitivity analysisCostRitonavir treatmentUnvaccinated personsVaccinated adultsPatient populationClinical trialsLower risk
2005
Cost-Effectiveness of HIV Screening for Incarcerated Pregnant Women
Resch S, Altice FL, Paltiel AD. Cost-Effectiveness of HIV Screening for Incarcerated Pregnant Women. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 38: 163-173. PMID: 15671801, DOI: 10.1097/01.qai.0000146598.40301.e6.Peer-Reviewed Original ResearchConceptsPediatric HIV casesPregnant womenIncarcerated pregnant womenAntiretroviral therapyHIV casesPediatric HIV infectionChild HIV transmissionHIV voluntary counselingHigh-risk populationRate of infectionDecision analytic modelHealth care expendituresHIV screeningHIV infectionVoluntary counselingHIV statusNewborn testingHIV transmissionHIV preventionPrison entrantsNew infectionsHIVTreatment resourcesNewborn screeningCorrectional facilities